75mg/3ml Diclofenac Sodium Injection (GMP medicine factory)

• Customization: Available
• Application: Relieving Fever and Analgesia
• Usage Mode: Injection
• Model NO.: 75mg/3ml
• Suitable for: All
• State: Liquid
• Shape: Oral Liquid
• Type: Biological Products
• Pharmaceutical Technology: Chemical Synthesis
• Drug Reg./Approval No.: 300490
• Drug Ad Approval No.: 300490
• Class: Pharmaceutical
• Transport Package: Box
• Specification: as buyer′s request
• Trademark: SHENGLU
• Origin: China
• HS Code: 2920901900
• Production Capacity: 100000000000000/Year

Product Description

Diclofenac Sodium injection relieving fever and analgesia
Diclofenac sodium, an organic compound with the chemical formula C14H10Cl2NNaO2, is mainly used as an antipyretic and analgesic, non-steroidal anti-inflammatory drug, commonly used in orthopedics for the treatment of various types of mild-to-moderate acute and chronic pain, such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and so on.
Cautions :
1, prohibited for patients allergic to this product, including patients with a history of asthma, urticaria or allergic reactions induced by aspirin or other non-retaining anti-inflammatory drugs.
2, with gastrointestinal bleeding or active peptic ulcer, bleeding, perforation of patients with a history of contraindication or caution.
3, As with other nonsteroidal anti-inflammatory drugs, due to reports showing an association between fluid retention and edema and nonsteroidal anti-inflammatory drug therapy. Therefore, patients with cardiac or renal insufficiency, patients with a history of hypertension, geriatric patients, patients taking diuretics or drug therapy that can significantly affect renal function, and patients with any cause of extracellular fluid loss (e.g., patients before or after major surgery) should be especially careful when administering this drug (see Contraindications). Monitoring of renal function is recommended as a prophylactic measure in such patients taking this product. In the event of renal adverse reactions, the patient usually recovers to pre-treatment status after discontinuation of the product.
Diclofenac may increase plasma lithium concentrations when used concomitantly with lithium. Plasma lithium levels should be measured when used with lithium.
5, for cardiac insufficiency oral digoxin patients, diclofenac can increase plasma digoxin concentration, plasma digoxin level should be monitored.
6, as with other non-residue anti-inflammatory drugs diclofenac and diuretics and antihypertensive drugs (such as beta-blockers, angiotensin-converting enzyme inhibitors) when used in conjunction with antihypertensive effect may be reduced. Therefore, when used in combination, the drug should be administered with caution and the patient's blood pressure should be checked regularly, especially in elderly patients. Patients should be adequately hydrated, and consideration should be given to monitoring renal function after the initial combination therapy is initiated and periodically thereafter, particularly in patients on combination diuretics and angiotensin-converting enzyme inhibitors, which may increase the risk of nephrotoxicity. When used in combination with potassium-preserving diuretics, elevated serum potassium levels may occur, causing hyperkalemia, making it necessary to monitor serum potassium concentrations. When used with furosemide, the latter's sodium excretion and antihypertensive effects are diminished.
7, other non-steroidal anti-inflammatory drugs and corticosteroids diclofenac and other non-steroidal anti-inflammatory drugs or corticosteroids when used in combination, may increase the frequency of gastrointestinal adverse reactions
Clinical studies have shown that diclofenac can be combined with oral hypoglycemic agents without affecting their clinical efficacy. However, there have been case reports of diclofenac requiring dose adjustments of oral hypoglycemic agents due to hypoglycemic and hyperglycemic reactions. Therefore, it is necessary to monitor blood glucose levels as a prophylactic measure for the combination.
9, for patients with rheumatoid arthritis, the use of non-steroidal anti-inflammatory drugs (including diclofenac) should be cautioned in the 24 hours before and after treatment with methotrexate, because methotrexate's blood concentration may be increased, and its toxicity may also increase.
10. As with other NSAIDs, the effect of diclofenac on renal prostaglandins may increase the nephrotoxicity of cyclosporine. Therefore, the use of patients receiving cyclosporine therapy should be lower than non-users. Probenecid decreases the excretion of the product and increases blood levels, thus increasing toxicity, so it is advisable to reduce the dose of the product when used together.


Storage :
Store tightly away from light.
Specification : AS buyer's request